Cargando…

Development and evaluation of a Markov model to predict changes in schistosomiasis prevalence in response to praziquantel treatment: a case study of Schistosoma mansoni in Uganda and Mali

BACKGROUND: Understanding whether schistosomiasis control programmes are on course to control morbidity and potentially switch towards elimination interventions would benefit from user-friendly quantitative tools that facilitate analysis of progress and highlight areas not responding to treatment. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Deol, Arminder, Webster, Joanne P., Walker, Martin, Basáñez, Maria-Gloria, Hollingsworth, T. Déirdre, Fleming, Fiona M., Montresor, Antonio, French, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059905/
https://www.ncbi.nlm.nih.gov/pubmed/27729063
http://dx.doi.org/10.1186/s13071-016-1824-7
_version_ 1782459500518703104
author Deol, Arminder
Webster, Joanne P.
Walker, Martin
Basáñez, Maria-Gloria
Hollingsworth, T. Déirdre
Fleming, Fiona M.
Montresor, Antonio
French, Michael D.
author_facet Deol, Arminder
Webster, Joanne P.
Walker, Martin
Basáñez, Maria-Gloria
Hollingsworth, T. Déirdre
Fleming, Fiona M.
Montresor, Antonio
French, Michael D.
author_sort Deol, Arminder
collection PubMed
description BACKGROUND: Understanding whether schistosomiasis control programmes are on course to control morbidity and potentially switch towards elimination interventions would benefit from user-friendly quantitative tools that facilitate analysis of progress and highlight areas not responding to treatment. This study aimed to develop and evaluate such a tool using large datasets collected during Schistosomiasis Control Initiative-supported control programmes. METHODS: A discrete-time Markov model was developed using transition probability matrices parameterized with control programme longitudinal data on Schistosoma mansoni obtained from Uganda and Mali. Four matrix variants (A-D) were used to compare different data types for parameterization: A-C from Uganda and D from Mali. Matrix A used data at baseline and year 1 of the control programme; B used year 1 and year 2; C used baseline and year 1 from selected districts, and D used baseline and year 1 Mali data. Model predictions were tested against 3 subsets of the Uganda dataset: dataset 1, the full 4-year longitudinal cohort; dataset 2, from districts not used to parameterize matrix C; dataset 3, cross-sectional data, and dataset 4, from Mali as an independent dataset. RESULTS: The model parameterized using matrices A, B and D predicted similar infection dynamics (overall and when stratified by infection intensity). Matrices A-D successfully predicted prevalence in each follow-up year for low and high intensity categories in dataset 1 followed by dataset 2. Matrices A, B and D yielded similar and close matches to dataset 1 with marginal discrepancies when comparing model outputs against datasets 2 and 3. Matrix C produced more variable results, correctly estimating fewer data points. CONCLUSION: Model outputs closely matched observed values and were a useful predictor of the infection dynamics of S. mansoni when using longitudinal and cross-sectional data from Uganda. This also held when the model was tested with data from Mali. This was most apparent when modelling overall infection and in low and high infection intensity areas. Our results indicate the applicability of this Markov model approach as countries aim at reaching their control targets and potentially move towards the elimination of schistosomiasis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-016-1824-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5059905
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50599052016-10-24 Development and evaluation of a Markov model to predict changes in schistosomiasis prevalence in response to praziquantel treatment: a case study of Schistosoma mansoni in Uganda and Mali Deol, Arminder Webster, Joanne P. Walker, Martin Basáñez, Maria-Gloria Hollingsworth, T. Déirdre Fleming, Fiona M. Montresor, Antonio French, Michael D. Parasit Vectors Research BACKGROUND: Understanding whether schistosomiasis control programmes are on course to control morbidity and potentially switch towards elimination interventions would benefit from user-friendly quantitative tools that facilitate analysis of progress and highlight areas not responding to treatment. This study aimed to develop and evaluate such a tool using large datasets collected during Schistosomiasis Control Initiative-supported control programmes. METHODS: A discrete-time Markov model was developed using transition probability matrices parameterized with control programme longitudinal data on Schistosoma mansoni obtained from Uganda and Mali. Four matrix variants (A-D) were used to compare different data types for parameterization: A-C from Uganda and D from Mali. Matrix A used data at baseline and year 1 of the control programme; B used year 1 and year 2; C used baseline and year 1 from selected districts, and D used baseline and year 1 Mali data. Model predictions were tested against 3 subsets of the Uganda dataset: dataset 1, the full 4-year longitudinal cohort; dataset 2, from districts not used to parameterize matrix C; dataset 3, cross-sectional data, and dataset 4, from Mali as an independent dataset. RESULTS: The model parameterized using matrices A, B and D predicted similar infection dynamics (overall and when stratified by infection intensity). Matrices A-D successfully predicted prevalence in each follow-up year for low and high intensity categories in dataset 1 followed by dataset 2. Matrices A, B and D yielded similar and close matches to dataset 1 with marginal discrepancies when comparing model outputs against datasets 2 and 3. Matrix C produced more variable results, correctly estimating fewer data points. CONCLUSION: Model outputs closely matched observed values and were a useful predictor of the infection dynamics of S. mansoni when using longitudinal and cross-sectional data from Uganda. This also held when the model was tested with data from Mali. This was most apparent when modelling overall infection and in low and high infection intensity areas. Our results indicate the applicability of this Markov model approach as countries aim at reaching their control targets and potentially move towards the elimination of schistosomiasis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-016-1824-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-12 /pmc/articles/PMC5059905/ /pubmed/27729063 http://dx.doi.org/10.1186/s13071-016-1824-7 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Deol, Arminder
Webster, Joanne P.
Walker, Martin
Basáñez, Maria-Gloria
Hollingsworth, T. Déirdre
Fleming, Fiona M.
Montresor, Antonio
French, Michael D.
Development and evaluation of a Markov model to predict changes in schistosomiasis prevalence in response to praziquantel treatment: a case study of Schistosoma mansoni in Uganda and Mali
title Development and evaluation of a Markov model to predict changes in schistosomiasis prevalence in response to praziquantel treatment: a case study of Schistosoma mansoni in Uganda and Mali
title_full Development and evaluation of a Markov model to predict changes in schistosomiasis prevalence in response to praziquantel treatment: a case study of Schistosoma mansoni in Uganda and Mali
title_fullStr Development and evaluation of a Markov model to predict changes in schistosomiasis prevalence in response to praziquantel treatment: a case study of Schistosoma mansoni in Uganda and Mali
title_full_unstemmed Development and evaluation of a Markov model to predict changes in schistosomiasis prevalence in response to praziquantel treatment: a case study of Schistosoma mansoni in Uganda and Mali
title_short Development and evaluation of a Markov model to predict changes in schistosomiasis prevalence in response to praziquantel treatment: a case study of Schistosoma mansoni in Uganda and Mali
title_sort development and evaluation of a markov model to predict changes in schistosomiasis prevalence in response to praziquantel treatment: a case study of schistosoma mansoni in uganda and mali
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059905/
https://www.ncbi.nlm.nih.gov/pubmed/27729063
http://dx.doi.org/10.1186/s13071-016-1824-7
work_keys_str_mv AT deolarminder developmentandevaluationofamarkovmodeltopredictchangesinschistosomiasisprevalenceinresponsetopraziquanteltreatmentacasestudyofschistosomamansoniinugandaandmali
AT websterjoannep developmentandevaluationofamarkovmodeltopredictchangesinschistosomiasisprevalenceinresponsetopraziquanteltreatmentacasestudyofschistosomamansoniinugandaandmali
AT walkermartin developmentandevaluationofamarkovmodeltopredictchangesinschistosomiasisprevalenceinresponsetopraziquanteltreatmentacasestudyofschistosomamansoniinugandaandmali
AT basanezmariagloria developmentandevaluationofamarkovmodeltopredictchangesinschistosomiasisprevalenceinresponsetopraziquanteltreatmentacasestudyofschistosomamansoniinugandaandmali
AT hollingsworthtdeirdre developmentandevaluationofamarkovmodeltopredictchangesinschistosomiasisprevalenceinresponsetopraziquanteltreatmentacasestudyofschistosomamansoniinugandaandmali
AT flemingfionam developmentandevaluationofamarkovmodeltopredictchangesinschistosomiasisprevalenceinresponsetopraziquanteltreatmentacasestudyofschistosomamansoniinugandaandmali
AT montresorantonio developmentandevaluationofamarkovmodeltopredictchangesinschistosomiasisprevalenceinresponsetopraziquanteltreatmentacasestudyofschistosomamansoniinugandaandmali
AT frenchmichaeld developmentandevaluationofamarkovmodeltopredictchangesinschistosomiasisprevalenceinresponsetopraziquanteltreatmentacasestudyofschistosomamansoniinugandaandmali